Drug
Eneboparatide
Eneboparatide: highest development phase Phase 3, developed by Alexion. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Alexion
Trials
| Drug | Phase | Indication |
|---|---|---|
| eneboparatide NCT05778071 | Phase 3 | Chronic Hypoparathyroidism |
Latest
No recent events.
Follow Eneboparatide on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.